<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291133</url>
  </required_header>
  <id_info>
    <org_study_id>21K/02/14</org_study_id>
    <nct_id>NCT02291133</nct_id>
  </id_info>
  <brief_title>Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)</brief_title>
  <acronym>ECT-HCC</acronym>
  <official_title>Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masa Bosnjak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate toxicity and effectiveness of electrochemotherapy with&#xD;
      bleomycin in treatment of primary liver tumors in clinical study phase I and II.&#xD;
&#xD;
      The study will include 10 patients in phase I clinical study and additional 15 patients in&#xD;
      phase II clinical study (or in the extension of the clinical study), which will fulfill&#xD;
      inclusion criteria.&#xD;
&#xD;
      Treatment effectiveness will be evaluated by DCE-US or CT perfusion, to detect early events&#xD;
      in tumor perfusion after ECT compared to tumor perfusion before ECT. Long term effectiveness&#xD;
      of the treatment will be evaluated by modified RECIST criteria, which will take into account&#xD;
      difference in size and density, determined from images obtained by CT perfusion of the&#xD;
      treated tumor nodules before and after ECT. Tumor volume will be calculated by following&#xD;
      formula , where a will be shorter and b longer tumor diameter.&#xD;
&#xD;
      The secondary objectives of the trial are to quantify the impact of the treatment on the&#xD;
      patient's quality of life, tolerance to the therapy and suitability for larger study to be&#xD;
      conducted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted on patients with primary liver tumors. 10 patients will be&#xD;
      included in phase I clinical study and additional 15 patients in phase II clinical study (or&#xD;
      in the extension of the clinical study).&#xD;
&#xD;
      Depending on the position of tumors, appropriate electrodes will be selected; hexagonal&#xD;
      needle electrodes with fixed geometry for tumors not larger than 3 cm in diameter, where&#xD;
      lower edge of the tumor is located up to 3 cm below the liver capsule or longer single needle&#xD;
      electrodes. Individual electrodes, positioned according to the prepared treatment plan will&#xD;
      be used for tumors up to 7 cm in diameter, or located near vena cava or large hepatic or&#xD;
      portal veins.&#xD;
&#xD;
      Electrochemotherapy will be performed within 8-28 min after intravenous in bolus&#xD;
      administration of bleomycin (15 mg/m2).&#xD;
&#xD;
      Triggering of electric pulses will be synchronized with ECG signals, through the ECG&#xD;
      triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart.&#xD;
&#xD;
      All patients will be treated after the procedure has been thoroughly described to them, and&#xD;
      have signed informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Toxicity Related to Electrochemotherapy</measure>
    <time_frame>After operation on day 7</time_frame>
    <description>Biochemistry, blood test and/or US</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Evaluation According to RECIST v1.1</measure>
    <time_frame>After operation on days 1, 7, 30, 60, 90, 120</time_frame>
    <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI/CT:&#xD;
Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Electrochemotherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrochemotherapy</intervention_name>
    <description>Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation</description>
    <arm_group_label>Electrochemotherapy treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cliniporator Vitae®</intervention_name>
    <description>Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.&#xD;
The maximum duration of procedure is 90 minutes, after liver mobilization.</description>
    <arm_group_label>Electrochemotherapy treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin PHC 15 e. (United States Pharmacopeia - USP)</intervention_name>
    <description>Intravenous in bolus administration of bleomycin (15 mg/m2)</description>
    <arm_group_label>Electrochemotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with primary liver tumors; hepatocellular carcinoma, intrahepatic&#xD;
             cholangiocarcinoma and other primary tumors not larger than 7 cm that are positioned&#xD;
             in unresectable liver area, near blood vessels in operable patients.&#xD;
&#xD;
          2. Patients with the progression of the disease (confirmed by radiological imaging) after&#xD;
             treatment with TACE, RFA or percutaneous alcohol ablation, which are not suitable for&#xD;
             potentially curative treatment, but with relatively good &quot;performance status&quot; and&#xD;
             Child-Pugh score &lt; 8.&#xD;
&#xD;
             Patients from group 1. and 2. are patients, in whom standard treatment procedures are&#xD;
             not eligible, so ECT will be the only therapeutic option. In patients with multiple&#xD;
             liver tumors, unresectable tumors which are also unsuitable for RAF will be treated by&#xD;
             ECT, whereas other tumors will be resected or treated by RAF.&#xD;
&#xD;
          3. Patients with tumors smaller tumors, not suitable for liver transplantation, but also&#xD;
             unsuitable for RFA treatment or percutaneous alcohol ablation because of the position&#xD;
             of the tumor. Electrochemotherapy will be as bridge therapy, till liver&#xD;
             transplantation.&#xD;
&#xD;
          4. Patients with tumors&gt; 4 cm in diameter, in difficult to reach locations, and patients&#xD;
             unsuitable for treatment with other treatment options.&#xD;
&#xD;
             Patients from group 3. and 4. are patients, potentially curable with standard&#xD;
             treatment. Electrochemotherapy in these patients will not affect the standard of care&#xD;
             of these patients, recommended in guidelines for HCC.&#xD;
&#xD;
          5. Electrochemotherapy is offered to the patients also when they refuse standard&#xD;
             treatments.&#xD;
&#xD;
          6. Histologically confirmed primary liver cancer and/or based on radiological imaging&#xD;
             laboratory tests confirmed primary liver cancer by multidisciplinary team for liver&#xD;
             tumors.&#xD;
&#xD;
          7. Age more than 18.&#xD;
&#xD;
          8. Life expectancy more than 3 month.&#xD;
&#xD;
          9. Performance status Karnofsky ≥ 70 or (World Health Organization) WHO &lt; or 2.&#xD;
&#xD;
         10. Treatment free interval 2-5 weeks, depending on the drugs used.&#xD;
&#xD;
         11. Patient must be mentally capable of understanding the information given.&#xD;
&#xD;
         12. Patient must give informed consent.&#xD;
&#xD;
         13. Patient must be discussed at the multidisciplinary team for liver tumors before&#xD;
             entering the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary primary tumor, except surgically treated noninvasive cancer of cervix, or&#xD;
             surgically or irradiated basal cell carcinoma&#xD;
&#xD;
          2. Visceral, bone or diffuse metastases.&#xD;
&#xD;
          3. Life-threatening infection and/or heart failure and/or liver failure and/or other&#xD;
             severe systemic pathologies.&#xD;
&#xD;
          4. Clinically significant ascites.&#xD;
&#xD;
          5. Significant reduction in respiratory function.&#xD;
&#xD;
          6. Age less than 18 years.&#xD;
&#xD;
          7. Coagulation disturbances (those who do not respond on standard treatment with&#xD;
             vitamin-K or fresh frozen plasma).&#xD;
&#xD;
          8. Cumulative dose of 250 mg/m2 bleomycin received.&#xD;
&#xD;
          9. Allergic reaction to bleomycin.&#xD;
&#xD;
         10. Impaired kidney function (creatinin &gt; 150 µmol/l).&#xD;
&#xD;
         11. Patients with epilepsy.&#xD;
&#xD;
         12. Patients with arrhythmias.&#xD;
&#xD;
         13. Patients with heart failure or pace maker.&#xD;
&#xD;
         14. Pregnancy.&#xD;
&#xD;
         15. Patient incapable of understanding the aim of the study or disagree with the entering&#xD;
             into the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihajlo Djokic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Blaz Trotovsek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregor Sersa, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Oncology Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Borut Stabuc, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Centre Ljubljana, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dragoje Stanisavljevic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Centre Ljubljana, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valentin Sojar, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Centre Ljubljana, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana, Ljubljana, Slovenia</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, Jarm T, Kos B, Pavliha D, Grcar Kuzmanov B, Cemazar M, Snoj M, Miklavcic D, Gadzijev EM, Sersa G. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol. 2014 Sep;110(3):320-7. doi: 10.1002/jso.23625. Epub 2014 Apr 30.</citation>
    <PMID>24782355</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <results_first_submitted>June 11, 2021</results_first_submitted>
  <results_first_submitted_qc>July 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2021</results_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Masa Bosnjak</investigator_full_name>
    <investigator_title>PhD, MPharm</investigator_title>
  </responsible_party>
  <keyword>Primary liver tumors</keyword>
  <keyword>Bleomycin</keyword>
  <keyword>Electrochemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02291133/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Electrochemotherapy Treatment</title>
          <description>Electrochemotherapy: Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation&#xD;
Cliniporator Vitae®: Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.&#xD;
The maximum duration of procedure is 90 minutes, after liver mobilization.&#xD;
Bleomycin PHC 15 e. (United States Pharmacopeia - USP): Intravenous in bolus administration of bleomycin (15 mg/m2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Electrochemotherapy Treatment</title>
          <description>Electrochemotherapy: Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation&#xD;
Cliniporator Vitae®: Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.&#xD;
The maximum duration of procedure is 90 minutes, after liver mobilization.&#xD;
Bleomycin PHC 15 e. (United States Pharmacopeia - USP): Intravenous in bolus administration of bleomycin (15 mg/m2)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" lower_limit="52" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Toxicity Related to Electrochemotherapy</title>
        <description>Biochemistry, blood test and/or US</description>
        <time_frame>After operation on day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Electrochemotherapy Treatment</title>
            <description>Electrochemotherapy: Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation&#xD;
Cliniporator Vitae®: Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.&#xD;
The maximum duration of procedure is 90 minutes, after liver mobilization.&#xD;
Bleomycin PHC 15 e. (United States Pharmacopeia - USP): Intravenous in bolus administration of bleomycin (15 mg/m2)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Toxicity Related to Electrochemotherapy</title>
          <description>Biochemistry, blood test and/or US</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECT-related adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-ECT-related within 24 h</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-ECT-related after 24 h</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Evaluation According to RECIST v1.1</title>
        <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI/CT:&#xD;
Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>After operation on days 1, 7, 30, 60, 90, 120</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Electrochemotherapy Treatment</title>
            <description>Electrochemotherapy: Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation&#xD;
Cliniporator Vitae®: Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.&#xD;
The maximum duration of procedure is 90 minutes, after liver mobilization.&#xD;
Bleomycin PHC 15 e. (United States Pharmacopeia - USP): Intravenous in bolus administration of bleomycin (15 mg/m2)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Evaluation According to RECIST v1.1</title>
          <description>Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI/CT:&#xD;
Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>complete response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>partial response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>stable disease (SD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>progressive disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7, 30, 60, 90, 120 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Electrochemotherapy Treatment</title>
          <description>Electrochemotherapy: Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation&#xD;
Cliniporator Vitae®: Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.&#xD;
The maximum duration of procedure is 90 minutes, after liver mobilization.&#xD;
Bleomycin PHC 15 e. (United States Pharmacopeia - USP): Intravenous in bolus administration of bleomycin (15 mg/m2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Clavien-Dindo Classification, Grade I</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Clavien-Dindo Classification, Grade II</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Gregor Serša</name_or_title>
      <organization>Institute of Oncology Ljubljana</organization>
      <phone>+38615874343</phone>
      <email>gsersa@onko-i.si</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

